EPX

Across TCGA pan-cancer cohorts, EPX mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated EPX data layer compared with 21 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher EPX mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated EPX expression acts as an unfavorable survival marker, although some lineages such as LUAD and CCRCC show a favorable association.

LUAD, CCRCC, and PDAC are the cancer types where EPX mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Quartile	All	0.964	0.861	.005	8	view →
CCRCC	DFS	Median	II,III,IV	0.816	0.207	.022	6	view →
PDAC	OS	Median	IV	0.836	0.491	.024	3	view →
LSCC	DFS	Tertile	All	1.000	0.605	.030	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

EPX–LUAD (DFS)

Open the LUAD breakdown →